Streetbeat News

Products Services

CNTA

The FDA has approved Centessa Pharmaceuticals' application to begin a Phase 1 clinical trial of ORX750, a new drug aimed at treating narcolepsy. This marks a significant step for Centessa in advancing its pipeline and potentially addressing a critical need in narcolepsy treatment.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:09 am

NOTE

Shares of FiscalNote (NOTE) are trading higher following the launch of its StressLens AI Agent, with a quantitative asset management firm becoming its first anchor customer.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:07 am

NOTE

FiscalNote has introduced StressLens, an AI agent designed to assist in risk assessment and management. The company also announced a quantitative asset management firm as its first major client for this new product.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:07 am

GE

Elekta and MIM Software Inc., recently acquired by GE HealthCare, have announced a collaboration to enhance radiation therapy treatment planning by integrating their leading solutions. This partnership aims to improve the delivery of cancer treatments.

Portfolio Pulse from Charles Gross

April 22, 2024 | 11:07 am

MRNA

Moderna has secured a contract with Brazil's Ministry of Health to supply 12.5 million doses of its mRNA COVID-19 vaccine, scheduled for delivery in Q2 2024. This follows the Brazilian Health Regulatory Agency's approval of Moderna's updated COVID-19 vaccine in March 2024.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:06 am

VZ

Verizon reported a total of 389,000 broadband net additions in Q1, indicating a significant growth in its broadband segment.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:01 am

BMY

Bristol Myers Squibb (BMY) and Cellares have entered into a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies, valued up to $380M in upfront and milestone payments. Cellares will optimize and automate select BMY CAR T cell therapies on its Cell Shuttle platform, dedicating multiple systems for BMY's exclusive use in Smart Factories across the U.S., EU, and Japan.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:00 am

PSTV

Plus Therapeutics Inc (NASDAQ:PSTV) is set to receive a $3 million funding recommendation from the Department of Defense for expanding its pediatric brain cancer clinical trial. The funding, expected to start in Q3 2024, will support the trial's expansion and extend the company's cash runway into the second half of 2025. Plus Therapeutics is focusing on a novel therapeutic, Rhenium (186Re) Obisbemeda, for treating pediatric high-grade glioma and ependymoma, with patient enrollment anticipated in the second half of 2024.

Portfolio Pulse from Vandana Singh

April 22, 2024 | 11:00 am

PSTV

Plus Therapeutics announced it now has $23 million in active awards to support its targeted radiotherapeutic pipeline, indicating strong financial backing and potential for accelerated development in its specialized medical treatments.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:00 am

RIVN

Rivian Automotive (NASDAQ:RIVN) is exploring variations of the previously scrapped tank turn feature, now focusing on off-road utility. The original feature was dropped due to concerns over driver safety and environmental impact. Rivian's Vice President of Software Development, Wassym Bensaid, discussed the potential for off-road targeted features that utilize aspects of the tank turn technology.

Portfolio Pulse from Anan Ashraf

April 22, 2024 | 10:49 am